Chemed Co. (CHE) Given Average Recommendation of “Hold” by Brokerages

Shares of Chemed Co. (NYSE:CHE) have been assigned an average rating of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $236.00.

A number of equities analysts have commented on CHE shares. Oppenheimer increased their target price on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th. Royal Bank of Canada increased their target price on Chemed to $232.00 and gave the company a “sector perform” rating in a report on Tuesday, October 31st. KeyCorp reissued a “hold” rating on shares of Chemed in a report on Friday, October 27th. Finally, ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st.

In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $228.45, for a total transaction of $228,450.00. Following the completion of the sale, the executive vice president now owns 36,809 shares of the company’s stock, valued at $8,409,016.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the sale, the director now directly owns 4,515 shares of the company’s stock, valued at approximately $909,682.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,179 shares of company stock valued at $10,729,699. Insiders own 4.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Acrospire Investment Management LLC acquired a new stake in Chemed during the second quarter worth $120,000. Pacad Investment Ltd. increased its stake in Chemed by 250.0% during the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after acquiring an additional 500 shares during the last quarter. IFP Advisors Inc increased its stake in Chemed by 1,504.5% during the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Chemed by 12.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares during the last quarter. Finally, MCF Advisors LLC purchased a new position in shares of Chemed during the third quarter worth $152,000. 97.71% of the stock is owned by institutional investors.

Chemed (NYSE:CHE) opened at $242.41 on Friday. Chemed has a fifty-two week low of $155.82 and a fifty-two week high of $251.00. The company has a market capitalization of $3,847.65, a P/E ratio of 53.87, a price-to-earnings-growth ratio of 5.09 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.

Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the prior year, the firm earned $1.73 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. equities research analysts expect that Chemed will post 4.73 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 13th were issued a $0.28 dividend. The ex-dividend date was Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.46%. Chemed’s dividend payout ratio is presently 24.89%.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.com-unik.info/2017/12/23/chemed-co-che-given-average-recommendation-of-hold-by-brokerages.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit